BR112017000529A2 - comprimido dispersível de misoprostol - Google Patents

comprimido dispersível de misoprostol

Info

Publication number
BR112017000529A2
BR112017000529A2 BR112017000529A BR112017000529A BR112017000529A2 BR 112017000529 A2 BR112017000529 A2 BR 112017000529A2 BR 112017000529 A BR112017000529 A BR 112017000529A BR 112017000529 A BR112017000529 A BR 112017000529A BR 112017000529 A2 BR112017000529 A2 BR 112017000529A2
Authority
BR
Brazil
Prior art keywords
misoprostol
dispersible tablet
pharmaceutically acceptable
acceptable salt
relates
Prior art date
Application number
BR112017000529A
Other languages
English (en)
Inventor
Elumalai Baskar
Arunachalam Malaiarasan
Venugopal PRABHAKARAN
Selvaraj SEKAR
Original Assignee
Azanta Danmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/329,023 external-priority patent/US20160008310A1/en
Priority claimed from EP14176821.8A external-priority patent/EP2965750B1/en
Application filed by Azanta Danmark As filed Critical Azanta Danmark As
Publication of BR112017000529A2 publication Critical patent/BR112017000529A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

a presente invenção refere-se a uma formulação farmacêutica sólida que compreende misoprostol ou um sal farmaceuticamente aceitável do mesmo. em particular, a invenção se refere a um comprimido dispersível que compreende misoprostol ou um sal farmaceuticamente aceitável do mesmo, fornecendo rotas de administração alternativas. o comprimido é particularmente adequado para amadurecimento cervical, indução de trabalho de parto, prevenção e/ou tratamento de hemorragia pós-parto ou pós-aborto.
BR112017000529A 2014-07-11 2015-07-10 comprimido dispersível de misoprostol BR112017000529A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/329,023 US20160008310A1 (en) 2014-07-11 2014-07-11 Misoprostol dispersible tablet
EP14176821.8A EP2965750B1 (en) 2014-07-11 2014-07-11 Misoprostol dispersible tablet
PCT/DK2015/050216 WO2016004960A2 (en) 2014-07-11 2015-07-10 Misoprostol dispersible tablet

Publications (1)

Publication Number Publication Date
BR112017000529A2 true BR112017000529A2 (pt) 2017-11-14

Family

ID=53879283

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000529A BR112017000529A2 (pt) 2014-07-11 2015-07-10 comprimido dispersível de misoprostol

Country Status (12)

Country Link
US (2) US11406615B2 (pt)
EP (1) EP3166597A2 (pt)
JP (2) JP6532529B2 (pt)
AU (1) AU2015287186B2 (pt)
BR (1) BR112017000529A2 (pt)
CA (1) CA2954086C (pt)
EA (1) EA039069B1 (pt)
MX (1) MX2017000399A (pt)
NZ (1) NZ727876A (pt)
RU (1) RU2017104233A (pt)
TN (1) TN2017000003A1 (pt)
WO (1) WO2016004960A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108434110B (zh) * 2018-04-28 2019-09-10 浙江仙琚制药股份有限公司 米索前列醇组合物、片剂及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9419566D0 (en) * 1994-09-27 1994-11-16 El Refaey Hazem Oral prostagladins for the routine management of the third stage of labour
IL150053A0 (en) * 1999-12-06 2002-12-01 Mendell Co Inc Edward Pharmaceutical superdisintegrant
GB0204771D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
TW200502000A (en) * 2003-03-28 2005-01-16 Kyowa Hakko Kogyo Kk Dividing tablet
WO2006125450A1 (en) 2005-05-26 2006-11-30 Atef Mohammed Mostafa Darwish Rectal and vaginal suppositories containing misoprostol
US20060286172A1 (en) 2005-06-03 2006-12-21 Anu Mahashabde Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
WO2007052289A2 (en) * 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
US8148560B2 (en) * 2005-09-23 2012-04-03 Teva Women's Health, Inc. Vaginal tablets comprising misoprostol and methods of making and using the same
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
KR101626873B1 (ko) * 2007-10-01 2016-06-02 라보라토리오스 레스비, 에스.엘. 구강붕해정제
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
CN102697746B (zh) * 2012-06-11 2014-03-19 广州朗圣药业有限公司 一种快速融变的米索前列醇阴道用组合物及其制备方法和应用
WO2014016394A1 (en) 2012-07-26 2014-01-30 Ferring B.V. Misprostol composition
CN102872024B (zh) * 2012-09-28 2015-06-17 天津市聚星康华医药科技有限公司 口腔内使用的米索前列醇药物组合物
CN103340837B (zh) * 2013-07-08 2018-04-27 天津市聚星康华医药科技有限公司 一种米索前列醇阴道泡腾片及其制备方法

Also Published As

Publication number Publication date
JP6921894B2 (ja) 2021-08-18
AU2015287186B2 (en) 2018-05-31
US20210322356A1 (en) 2021-10-21
CA2954086A1 (en) 2016-01-14
AU2015287186A1 (en) 2017-01-19
NZ727876A (en) 2018-05-25
TN2017000003A1 (en) 2018-07-04
WO2016004960A2 (en) 2016-01-14
EA039069B1 (ru) 2021-11-30
JP2017520628A (ja) 2017-07-27
CA2954086C (en) 2020-03-31
JP2019147831A (ja) 2019-09-05
EP3166597A2 (en) 2017-05-17
MX2017000399A (es) 2017-08-10
RU2017104233A3 (pt) 2018-12-18
JP6532529B2 (ja) 2019-06-19
WO2016004960A3 (en) 2016-03-17
US20220347145A1 (en) 2022-11-03
EA201692536A1 (ru) 2017-06-30
RU2017104233A (ru) 2018-08-13
US11406615B2 (en) 2022-08-09

Similar Documents

Publication Publication Date Title
EP3159006A4 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
IL251687A0 (en) Medicinal composition for use in treatment to prevent vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery
MD4763C1 (ro) Compoziţie farmaceutică
IN2014DN09240A (pt)
BR112017019364A2 (pt) dispersões sólidas
BR112017000529A2 (pt) comprimido dispersível de misoprostol
BR112017028025A2 (pt) complexo de ferro-carboidrato para o tratamento da deficiência de ferro de um feto ou de um bebê
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
BR112018007374A2 (pt) composição farmacêutica
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
JO3321B1 (ar) قرص قابل للتشتت من ميزوبروستول
BR112017003900A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
TH167850B (th) (r)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับการใช้ ในยารักษาโรค

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]